The People Have Spoken: Mercy’s Use of Bioactive Glass Technology Recognized at SAWC Fall 2024
Mercy’s innovative use of bioactive glass technology to treat challenging wounds was recently recognized at the Symposium on Advanced Wound Care (SAWC) Fall 2024 when three clinical posters highlighting their work were voted among the 15 People’s Choice Award nominees.
Voted on by SAWC attendees, the three award nominees highlighted several cases where Mercy physicians utilized Mirragen®, Engineered Tissue Solution’s (ETS) borate-based bioactive glass fiber matrix, to treat a variety of wounds, including non-healing diabetic foot ulcers, chronic foot ulcers, and pilonidal cysts.
“At SAWC, providers across the country clearly recognized the value of Mercy’s pioneering work with Mirragen,” says AJ Ford, CEO of ETS. “We are incredibly grateful to partner with organizations at the forefront of wound care like Mercy, providing their patients with the latest innovations and best possible treatment in their time of need. It’s exciting to see the Mercy’s success using bioactive glass to treat difficult-to-heal wounds, and we look forward to seeing their research translate into even greater patient successes in the future.”
Mirragen facilitates quality tissue formation without the traditional risk of infection tissue-based products have, all in an easy to use, versatile form factor. Additional information about this groundbreaking synthetic skin substitute is available at ets123.com.
Mirragen Advanced Wound Matrix is intended for use in the management of wounds under the supervision of a healthcare professional. Consult the IFU for a complete list of indications and safety information
Mercy Poster Award Nominees
Effective Use of Bioactive Glass in the Treatment of Pilonidal Cysts
Authors: Kerry T. Thibodeaux, MD, CWSP, FACS; Darshan B Thakkar, MD; Donald William Buck II, MD; Tracy Winkley, PT, CWS, CLT
Mirragen was utilized to effectively treat pilonidal cystectomy wounds, resulting in positive healing outcomes in all five cases. All patients exhibited either complete healing or significant improvement in wound size and condition during the study period.
Enhancement of Wound StO2 Using a Novel Borate-based Bioactive Glass Matrix: a Pilot Case Series
Authors: Amy L. Couch, MD; Kelly Roberts, FNP, CWS; Erin Buchness, RN, MAPWCA
Wound types treated were: traumatic (n=1), venous insufficiency (n=3), pressure (n=1), pyoderma gangrenosum (n=1) and post-surgical breast ulcer (n=1). Wounds were present an average of 3.7 years (range: 0.1-16.0 years) prior to initial bioactive-glass wound matrix (BGWM) application and mean wound volume at start of BGWM was 10.6 cm3 (range: 0.03-25.0 cm3). Limb salvage was achieved for all patients and wounds were 96%-100% closed in an average of 8.0 weeks (range: 6.0-10.0 weeks) during BGWM use. For all wounds, NIRS images showed progressively improved wound bed StO2 which correlated positively with wound size reduction.
All Mirragen-treated wounds in this pilot series exhibited a positive healing trajectory with increased granulation tissue formation and enhanced wound bed StO2, despite absence of wound bed debridement.
Effect of bioactive glass wound matrix on small fiber neuropathy density in non-healing diabetic foot ulcers
Author: Dr. Raymond Abdo
Six non-healing diabetic wounds resolved after application of Mirragen. Of these resolved wounds, three wounds had an increased small nerve fiber density, two wounds further decreased in small nerve density, and one wound had no measurable change as compared to the initial biopsy prior to the application of the bioactive glass wound matrix.
